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 Abstract    
Engineering a Synthetic Extra-Cellular Matrix for 
In Vitro Cartilage Tissue Production 
 
In this study, growth factor binding found in natural extra-cellular matrix (ECM) was mimicked by a 
modified polymer scaffold that could attract either Insulin-Like Growth Factor-I (IGF-I), a growth factor 
known to stimulate ECM production by chondrocytes, and Transforming Growth Factor-β1 (TGF-β1), a 
growth factor known to induce chondrogenesis in mesenchymal stem cells. 
 
Short growth factor-binding peptides were synthesized and covalently attached to an alginate polymer 
scaffold.  Using self-assembled monolayer (SAM) chemistry, these modified alginate layers were 
characterized using Imaging Ellipsometry (IE).  Affinity of each growth factor for its respective synthetic 
peptide was quantified via Surface Plasmon Resonance (SPR).  The density of binding peptides bound to 
alginate was determined using Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy 
(ATR-FTIR).  Computational diffusion modeling was used to design an ELISA-based diffusion 
experiment.  Mesenchymal stem cells and chondrocytes were grown in chemically modified-alginate beads 
with and without added growth factor; modification increased ECM production in both kinds of cells.  
Thus, through this novel system of peptide-modified alginate scaffolds, growth factors were specifically but 
non-covalently retained by alginate, allowing for controlled release of growth factors.
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Owens  iii1 Introduction     
Loss or failure of an organ or tissue is one of the most frequent and costly problems in human health care.  
Yearly, more than one million surgical procedures in the United States involve the replacement of bone or 
cartilage, including more than 500,000 arthroplastic procedures and total joint replacements.
1, 2  
Degenerative diseases such as osteoarthritis are the major cause of loss of cartilage.  Osteoarthritis alone 
affects more than 10% of Americans older than 60 years.
3  Trauma to intervertebral disk and meniscus 
cartilage are primary sources of cartilage damage in younger patients.
4  Additionally, reconstruction of 
craniofacial defects such as cleft palate
5 or microtia
6 often require the use of cartilage transplantation.  
 
1.1 Cartilage structure & composition 
There are four primary types of cartilage, each distinguished by specific cellular components and functions: 
hyaline cartilage, costochondral cartilage, elastic cartilage, and fibrocartilage.
4  
 
 
Hyaline 
 
Costochondral Elastic  Fibrocartilage 
Articular joints  Rib  Ear  Tendon insertion site 
Nose  Growth plate    Ligament insertion site 
Trachea    Meniscus 
Intervertebral disk (NP)     Intervertebral  disk  (AP) 
Vertebral  end  plate     
 
Table 1.1. Summary of mammalian cartilage types and locations.
4
 
The composition of the extracellular matrix (ECM) that surrounds chondrocytes in vivo determines the 
functional behavior of cartilage.  For hyaline cartilage, the ECM generally is composed of 50% fibrous 
matrix (including collagens II, IX, and IX, as well as occasional elastic fibers) and 50% ground substance, 
including proteoglycans and non-collagenous proteins.
7  Collagens play a key role in the matrix structure of 
the ECM, as the collagen fiber triple-helices are strong in tension and resist osmotic pressure created by 
surround ECM material.   Proteoglycans are composed of glycosaminoglycan (GAG) carbohydrate chains 
covalently bound to a protein core.  Aggrecan is the largest proteoglycan, and is a key component in 
distributing load in weight-bearing joints.  Other proteins include decorin, a small proteoglycan that has 
been shown to bind to growth factors,
8 and hyaluronic acid, which acts as a backbone to which aggrecan 
Owens  11 Introduction     
molecules bind to form aggregates.  These macromolecular components are chemically and mechanically 
connected to form a continuous three-dimensional network. 
 
 
Figure 1.1 Summary of macromolecular constituents of cartilage ECM. The ECM is composed of proteoglycans 
attached to a backbone of hyaluronic acids that is intertwined among collagen fibrils.  From Moreland.
9
 
1.2 Cartilage repair methods 
Loss of or damage to cartilage tissue is particularly problematic because cartilage has very limited potential 
to spontaneously heal.  Adult articular cartilage is avascular, aneural, and contains no lymphatic drainage; 
in fact, articular cartilage defects larger than 4 mm in diameter rarely regenerate.
10   
 
Surgical interventions to repair cartilage are listed in Table 1.2.  Unfortunately, no method has been shown 
to create superior quality articular cartilage repair tissue.  Arthroscopic lavage and debridement do not 
induce repair of cartilage tissue, but rather provide temporary relief of osteoarthritis symptoms.  Bone 
marrow stimulation produces primarily fibrocartilage, which due to structural properties different from 
articular cartilage, does not offer a long-term cure.  Soft tissue grafts can produce repair tissue that is 
similar to hyaline cartilage, but the technique is limited by tissue graft availability and a tendency toward 
ossification of repair tissue. 
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Surgical Technique 
 
Method 
Arthroscopic Lavage 
& Debridement 
 
Damaged articular cartilage tissue is rinsed or removed 
Bone Marrow Stimulation 
  Pridie Drilling 
  Abrasion arthroplasty 
Microfracture 
 
Subchondral bone marrow underlying regions of damaged articular 
cartilage is damaged to stimulate a repair reaction
11
Soft tissue grafts 
 
Periosteum or perichondrium are transplanted to full thickness 
defects of articular cartilage 
 
Autologous Cartilage Tissue 
Transplantation 
 
Healthy cartilage is excised, chondrocytes are expanded in culture 
and reinjected into articular cartilage defect 
 
Table 1.2. Summary of current surgical techniques to repair cartilage defects. 
Adapted from Gilbert
12 and Minas et al.
13
 
In 1994, Brittenberg et al
2 successfully reported autologous chondrocyte implantation using a monolayer 
culture system to treat cartilage defects.  In autologous cartilage tissue transplantation, a healthy biopsy is 
excised from a non-load-bearing region of articular cartilage.  The chondrocytes are released by enzymatic 
digestion and expanded in culture. After the defect has been sutured, the cultured autologous chondrocytes 
are injected into the defect site.
14 In the United States and Europe, similar cell processing has been 
conducted on a commercial basis. 
 
However, autologous tissue transplantation has several disadvantages, including reacquisition of 
phenotypes of dedifferentiated chondrocytes and uneven distribution of transplanted chondrocytes.
15 
Additional difficulties have been encountered due to scarcity of donor sites, cell death during harvest, and 
difficulties integrating transplanted cartilage into the implant site.  In response to a growing demand for 
cartilage tissue replacements, engineered cartilage tissues have thus been proposed as a method to repair or 
replace injured or diseased cartilage. 
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1.3 Matrix materials & synthetic scaffolds 
Synthetic ECMs, or tissue scaffolds, are being used to replace many structural functions of the native ECM.  
These engineered ECMs provide mechanical integrity to new cartilage tissue, organize cells into a stable 
three-dimensional architecture, and provide a hydrated space for the diffusion of nutrients and metabolites 
to and from the cells.  As in autologous tissue transplantation, cells are removed from the body, grown in 
culture, applied to the synthetic scaffold material in vitro, and then transplanted.  The cells in the scaffold 
should then produce ECM components in vivo, which resemble native cartilage as closely as possible in its 
functional and morphological properties. 
 
However, one key difficulty in production of synthetic cartilage tissue in artificial scaffolds is significant 
loss of regulatory proteins after initial transplantation, which are essential components for tissue 
development and proliferation.  Cell signaling through bound ECM molecules is a requirement for survival 
of most cell types; cell signaling orchestrates critical roles in many cellular functions including migration, 
proliferation, differentiation, and apoptosis.
7  Due to reduction of cellular interaction with natural ECM 
proteins, researchers have not yet produced mechanically functional, clinically useful tissue that can match 
tissues produced under normal physiological conditions using either transplanted chondrocytes (cartilage 
producing cells) or mesenchymal stem cells (chondrocytes progenitor cells).   
 
Figure 1.2. Molecular structure of alginate monomers 
Most strategies for tissue engineering are based on the use of biodegradable polymers as temporary scaffold 
materials for differentiated chondrocytes or mesenchymal stem cells.  Various hydrogels have been used as 
synthetic ECMs for cell immobilization, transplantation, and tissue engineering.  Alginates are naturally 
derived polysaccharides that have been extensively used as hydrogel synthetic ECMs.  Alginate was chosen 
as the scaffolding material for this experiment 
because alginate polymers are regarded as an 
ideal synthetic matrix material, i.e.,  their 
interactions with cells are well characterized; 
they are amenable to sterilization and storage; 
and they may be chemically modified with 
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simple chemistries.  Structurally, alginate is composed of (1-4)-linked β-D-mannuronic acid (M units) and 
α-L-guluronic acid (G units).  The alginate molecule is a block copolymer composed of regions of 
sequential M units, regions of sequential G units, and regions of randomly organized M and G units.
16 
However, due to its hydrophilic nature, alginate discourages protein adsorption.  Therefore, mammalian 
cells are unable to interact specifically with alginate hydrogels.
17  Scaffolds utilizing hydrophobic materials 
may bind cells and proteins through physical adsorption; however, this is a poor substitute for natural 
ECM.   
 
1.4 Growth factors 
Our tissue engineering approach to cartilage repair involves not only cells and matrices, but also signaling 
molecules.  In order to create structurally and functionally competent cartilage repair tissue, our primary 
interest was to create biomimetic binding proteins to bind two key growth factors that have well known 
effects on cartilage-producing cells.  By non-covalently binding cell signaling proteins to alginate, a 
composite hydrogel composed of cells, bound growth factors, and alginate may allow for sustainable tissue 
growth and repair. 
 
1.4.1 Insulin-Like Growth Factor-I 
The first growth factor of interest, Insulin-Like Growth Factor-I (IGF-I), is a growth regulatory protein 
involved in stimulation of cellular proliferation, cartilage sulfonation, DNA synthesis, proteogylcan 
synthesis, and glycosaminoglycan synthesis; it is essential for normal mammalian growth and 
development.
18  IGF-I can also enhance cell-based repair of articular cartilage.
19 IGF-I is a single 
polypeptide chain of 70 amino acids that can be bound by one of six different insulin-like growth factor 
binding proteins (IGFBPs), which act as important regulators of IGF action.  
 
Most of the IGF-I molecules in serum are found complexed with IGFBP-3.
20  To a lesser degree, IGFBP-5 
also forms complexes with IGF-I.
21  An even smaller proportion of IGF-I is carried by other IGFBPs, and 
less than 1% of IGF-I circulates in the free (unbound) form.
20  All human IGFBPs contain between 216 and 
289 amino acids organized into three domains of approximately equal size with conserved N-terminal and 
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C-terminal domains joined by a “linker” L-domain.
22  Both the N- and C-domains of IGFBPs participate in 
binding to IGF. 
    
 
   
    N-domain                   L-domain                   C-domain 
 
Figure 1.3. Structure of IGFBPs in three domains, each of which contributes to chemical binding properties.  Regions 
of the N- and C-terminal domains involved in IGF binding are enclosed in red boxes.  Adapted from Bach et al.
22
 
During the last decade, several publications have reported an increasingly smaller N-domain fragment of 
IGFBP-5 that alone can bind IGF-I with only 10 to 1000 times lower affinity than the full length IGFBP-5.  
A critical 40-amino acid sequence derived from the N-domain region of IGFBP-5 was determined in 1998 
by Kalus et al.
18, 23   Termed “Mini-BP-5,” this sequence was shown to have a 37 nM affinity for IGF-I, 
compared to 3.7 nM for the entire binding protein, as determined by a surface plasmon resonance binding 
kinetics study.  Another small segment, called “10 kDa IGFBP-5,” was also analyzed; however, its binding 
was much less than the other analytes considered. 
 
Analyte Ligand 
 
kon 
10
6 / Ms 
 
koff 
1 / s  KD
IGFBP-5 IGF-I  1.2  4.4E-03  3.7  nM 
Mini-IGFBP-5 IGF-I  5.1  1.9E-01  37  nM 
10 kDa IGFBP-5  IGF-I  1.9  3.0E-01  158 nM 
 
Table 1.3. Binding affinity values for IGFBP-5 and small peptide sequences for IGF-I.  Adapted from Kalus et al.
18, 23
 
The greater affinity to the full IGFBP-5 is a result of more rapid dissociation of IGF-I from the N-terminal 
domain than from the full-length IGFBP-5.   This mini-BP-5 sequence consists solely of a compact three-
stranded β-sheet and a short α-helix, stabilized by two disulfide bonds.
22 The sequence alignment below 
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shows the location of mini-BP-5 within the IGFBP-5 molecule, as well as a smaller sequence, highlighted 
in yellow, upon which much of the work in this thesis is based. 
 
                     10        20        30        40        50        60 
                      |         |         |         |         |         | 
IGFBP-3       -----MHPARPALWAAALTALTLLRGPPVARAGAGAVGAGPVVRCEPCDARALSQCAPPP 
IGFBP-5       --------------MVLLTAVLLLLA---AYAGP-AQSLGSFVHCEPCDEKALSMCPPSP 
IGFBP-6       -----------MTPHRLLPPLLLLLALLLAASPG-----GALARCPGCGQGVQAGCPGGC 
IGFBP-4       -----------MLPFGLVAALLLAAGP--RPSLG-----DEAIHCPPCSEEKLARCRP-P 
IGFBP-2       MLPRVGCPALPLPPPPLLPLLPLLLLLLGASGGGGGARAEVLFRCPPCTPERLAACGPPP 
IGFBP-1       ---------MPEFLTVVSWPFLILLSFQIGVAAG----APQPWHCAPCTAERLGLCPPVP 
                                 . :        .           :*  *     . *     
                     70        80        90       100       110       120 
                      |         |         |         |         |         | 
IGFBP-3       TAP-------------ACTELVREPGCGCCLTCALREGDACGVYTERCGTGLRCQPRPAE 
IGFBP-5       LG---------------C-ELVKEPGCGCCMTCALAEGQSCGVYTERCAQGLRCLPRQDE 
IGFBP-6       VE--------------EEDGGSPAEGCAEAEGCLRREGQECGVYTPNCAPGLQCHPPKDD 
IGFBP-4       VG---------------CEELVREPGCGCCATCALGLGMPCGVYTPRCGSGMRCYPPRGV 
IGFBP-2       VAPPAAVAAVAGGARMPCAELVREPGCGCCSVCARLEGEACGVYTPRCGQGLRCYPHPGS 
IGFBP-1       AS---------------CPEISRPAGCGCCPTCALPMGAACGVATARCAQGLSCRALPGE 
                                      **. .  *    *  *** * .*. *: * .     
                    130       140       150       160       170       180 
                      |         |         |         |         |         | 
IGFBP-3       QYPLRALLNGRGFCANASAAGSLSTYLPSQPAPGNISESEEEHNAGSVESQVVPSTHRVT 
IGFBP-5       EKPLHALLHGRGVCLNE------KSYREQVKIERDSREHEEPTTSEMAEETYSPKIFRPK 
IGFBP-6       EAPLRALLLGRGRCLPA---------RAPAVAEENPKESK---P--QAGTARPQDVN--- 
IGFBP-4       EKPLRTLMHGQGVCTELS---------EIEAIQESLQTSDKDESEHPNNSFNPCSAH--- 
IGFBP-2       ELPLQALVMGEGTCEKRR-------DAEYGASPEQVADNGDDHSEGGLVENHVDSTMNML 
IGFBP-1       PRPLHALTRGQGACVPEP--------AAPATSTLSSSQHEEAKAAVVSADELSESPE--- 
               **::*  *.* *                    .                   .      
                    190       200       210       220       230       240 
                      |         |         |         |         |         | 
IGFBP-3       ----DSKFHPLHAKMDVIKKGHARDSQRYKVDYESQSTDTQN-FSSESKRETEYGPCRRE 
IGFBP-5       ----HTRISELKAEAVKKDRRKKLTQSKFVGGAENTAHPRII-SAPEMRQESEQGPCRRH 
IGFBP-6       ------R----------------RDQQRNPGTSTTPSQP-----NSAGVQDTEMGPCRRH 
IGFBP-4       ------------------D---HRCLQKHMAKIRDRSKMKIVGTPREEPRPVPQGSCQSE 
IGFBP-2       GGGGSAGRKPLKSGMKELAVFREKVTEQHRQMGKGGKHHLGLEEPKKLRPPPARTPCQQE 
IGFBP-1       ---------MTEEQLLDSFHLMAPSREDQPILWNAISTYSSMRAREIADLKKWKEPCQRE 
                                       .                            .*: . 
                    250       260       270       280       290       300 
                      |         |         |         |         |         | 
IGFBP-3       MEDTLNHLKFLNVLSPR-------GVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVD-KY 
IGFBP-5       MEASLQELKASPRMVPR-------AVYLPNCDRKGFYKRKQCKPSRGRKRGICWCVD-KY 
IGFBP-6       LDSVLQQLQTEVYRGAQ-------TLYVPNCDHRGFYRKRQCRSSQGQRRGPCWCVD-RM 
IGFBP-4       LHRALERLAASQSRTHED----LFIIPIPNCDRNGNFHPKQCHPALDGQRGKCWCVDRKT 
IGFBP-2       LDQVLERISTMRLPDERGPLEHLYSLHIPNCDKHGLYNLKQCKMSLNGQRGECWCVNPNT 
IGFBP-1       LYKVLERLAAAQQKAGD----EIYKFYLPNCNKNGFYHSKQCETSLDGEAGLCWCVYPWS 
             :   *:.:                 . :***::.* :. :**. : . . * ****     
                    310       320       330 
                      |         |         | 
IGFBP-3       GQPLPGYDTKGKDDVHCLSVQSQ------------- 
IGFBP-5       GMKLPGMEYVDG-DFQCHTFDSSNVE---------- 
IGFBP-6       GKSLPGSPDGNG-SSSCPTGSSG------------- 
IGFBP-4       GVKLPGGLEPKG-ELDCHQLADSFQE---------- 
IGFBP-2       GKLIQGAPTIRG-DPECHLFYNEQQEARGVHTQRMQ 
IGFBP-1       GKKIPGSLETRG-DPNCHQYFNVHN----------- 
             *  : *       .  *    .              
 
Figure 1.4. Sequence alignment of IGFBP-1 to -6 performed by the author using protein sequences from NCBI Entrex 
Protein; sequences aligned using CLUSTALW Network Protein Sequence Analysis.
24  Highly conserved residues are 
indicated by red shading.  “Mini-BP-5” is bolded.  Residues that were selected for this study are highlighted in yellow.  
The linker domain is underlined. 
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Because this and other studies have proposed that the N-terminal region of IGFBP-5 contains a 
hydrophobic binding pocket between residues 38 and 74 that is required for high-affinity binding, Imai et 
al. developed a site-directed mutagenesis study to determine the importance of several of the amino acids in 
this region.  When residues Lys
68, Pro
69, Leu
70, Leu
73, and Leu
74 in IGFBP-5 were altered (changing the one 
charged residue, Lys 
68, to a neutral one and the four hydrophobic residues to nonhydrophobic residues), 
affinity for IGF-I decreased by 1000-fold.  Therefore, this specific group of hydrophobic amino acids 
within the N-terminal third of IGFBP-5 appears critical for high affinity binding of IGF-I.
25
 
Below is shown the crystal structure of the IGF-I complexed with mini-BP-5.  The sequence 
K68P69L70H71A72L73L74 within mini-BP-5 interacts with IGF-I within 4 Å, the limit for electrostatic 
interactions.  Based on this data, as well as previous studies, K68P69L70H71A72L73L74 was chosen for this 
study as a putative short binding sequence for IGF-I. 
 
       
 
Figure 1.5. (Left) IGFBP-5 (left) bound to IGF-I (right).  The binding sequence, KPLHALL, being tested in this study 
is labeled and highlighted in blue; (Right) Three-dimensional structure of KPLHALL. 
 
1.4.2 Transforming Growth Factor-β1 
The second growth factor of interest is transforming growth factor-beta (TGF-β1), another potent growth 
regulatory protein, that is involved in wound healing, growth and differentiation, angiogenesis, and 
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chondrogenesis of mesenchymal stem cells.
26 TGF-β1 is a disulfide-linked homodimer of two 112 amino 
acid polypeptides with a characteristic pattern of 9 cysteines.  Recently, it has been found that 
thrombospondin-1 (TSP-1), a glycoprotein, is a key activator and regulator of TGF-β1 expression and 
signalling.
27-30  In 1995, Schultz-Cherry et al. found that the hexapeptide GGWSHW, derived from TSP-1, 
binds strongly to the sequence VLAL in active TGF-β1.
31, 32  Therefore, we have selected the amino acid 
sequence GGWSHW for study, as well as a control sequence GGASHA that was demonstrated by Murphy-
Ullrich (unpublished data) to have no specific interaction with TGF-β1.  
 
   
 
Figure 1.6. (Left) Crystal structure of thrombospondin-1, with the GGWSHW binding sequence highlighted in blue; 
(Right) Structure of TGF-β1, with the VLAL interaction sequence highlighted in red.  Two binding sites are present as 
TGF-β1 is a homodimer. 
 
1.5 Study Objectives 
By using simple carbodiimide chemistry to attach these two short amino acid sequences from the binding 
areas of TSP-1 and IGFBP-5 to an alginate scaffold, it is hoped that growth factors will bind in a manner 
similar to that which occurs in vivo to improve the characteristics of engineered cartilage tissue.  By non-
covalently binding growth factors, we hope to be able to tailor specific cell-alginate interactions.   
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Growth Factor  Binding Protein 
Peptide-Modified Alginate 
Figure 1.7.  Project schematic; A short binding sequence (circled) from IGFBP-5 is covalently bound to alginate.  This 
modified alginate attracts and non-covalently binds growth factors. 
 
In order to characterize binding of IGF-I and TGF-β1 to an artificial ECM composed of peptide-modified 
sodium alginate, three studies were performed, each involving several different assays.  This experiment 
began under the assumption that the sequences GGWSHW and KPLHALL bind to TGF-β1 and IGF-I, 
respectively, based on literature and sequence alignment studies performed by the author.  The three studies 
include a binding kinetics study, in which the binding constants and characteristics of binding peptide-
modified alginate on a molecular scale will be determined; a controlled-release study, in which the 
macromolecular diffusion and release properties of modified-alginate beads will be modeled and tested; 
and a cellular study, in which growth response of chondrocytes and mesenchymal stem cells to this 
modified alginate will be monitored.  Through this series of experiments, it will be possible to determine if 
binding peptide-modified alginate can act as a new scaffold material for in vitro cartilage tissue production. 
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2.1 Reagents and other chemicals 
The following chemicals were used:  ProNova UltraPure Low Viscosity Guluronate (UP LVG), a high G 
content alginate, was purchased from ProNova Biopolymers (Norway).  Lyophilized human transforming 
growth factor-β1 (TGF- β1) and recombinant human insulin-like growth factor-I (IGF-I) were purchased 
from PeproTech (Rocky Hill, NJ).  Trace tris hydroxymethylaminoethane buffer contaminants were 
removed from lyophilized TGF- β1 using a 5 kDa MWCO size-exclusion spin filter (Novagen).  11-amino-
1-undecanethiol, hydrochloride (AUT; >99% purity) was purchased from Dojindo Laboratories 
(Kumamoto, Japan).  Ethylenediamine was obtained from Aldrich Chemical Co. (Milwaukee, WI).  All 
aqueous solutions were prepared using reagent grade deionized water. 
 
The binding hexapeptides Glycine-Glycine-Tryptophan-Serine-Histidine-Tryptophan and Glycine-Glycine-
Asparagine-Serine-Histidine-Asparagine, abbreviated with the single letter amino acid abbreviations 
GGWSHW and GGASHA, respectively, were produced by the Protein Core facilities at the University of 
Alabama at Birmingham.  The peptide Glycine-Glycine-Glycine-Lysine(Dde)-Proline-Leucine-Histidine-
Asparagine-Leucine-Leucine, abbreviated GGGKPLHALL, was purchased at 80% purity from Innovagen 
AB (Sweden).  The additional 3 glycines at the N-terminus of this synthetic peptide sequence were added 
in order to provide a linker layer that would more fully expose the active peptides in the sequence once the 
peptide was bound to a surface.  The lysine on this sequence was protected from unwanted chemical 
reactions by a Dde protecting group; this was removed using 5% hydrazine, anhydrous (Sigma) in 
dimethylformamide (DMF).  Unless stated otherwise, all other chemicals were purchased from Sigma 
Chemical Co. (St. Louis, MO) and were used as received without further purification. 
 
2.2 Chemical modification of alginate 
In order to attach the binding peptides GGWSHW and KPLHALL to alginate, aqueous carbodiimide 
chemistry was utilized.  Alginate chemistry was performed in 1% (w / v) UP LVG alginate solutions in 0.1 
M MES buffer (pH 6.5, 0.3 M NaCl) for 20 hours.  1-ethyl-(dimethylaminopropyl) carbodiimide (EDC), a 
water-soluble carbodiimide, was used to form amide linkages between the amine group on the amino 
terminus of the peptide sequences and the carboxylate groups on the alginate polymer backbone.
33 The co-
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reactant N-hydroxysulfosuccinimide (sulfo-NHS, Pierce, Rockford, IL) was used to stabilize the reactive 
EDC-intermediate against a competing hydrolysis reaction, raising the efficiency of amide bond 
formation,
34 and was dissolved in the alginate solution at a ratio of 1:2 to EDC.
35   1 mg of synthesized 
peptide per gram alginate was added after 5 minutes of EDC activation.
36  The alginate product was 
purified by dialysis (3500 MWCO) against distilled H2O for four days and lyophilized until dried. 
  PEPTIDE 
PEPTIDE
 
 
Figure 2.1. Covalent attachment of short peptides to alginate 
 
2.3 Binding kinetics study 
As outlined in the introduction of this thesis, the first aim of this project was to characterize the binding 
kinetics present between peptide-modified alginates and their respective growth factors.   The non-covalent 
binding between free growth factor (GFFree) and binding peptide (BP) can be formulated as: 
 
GFFree + BP
koff
←
→
kon
GFBound
     (Equation  1) 
 
The initial concentration of free growth factor is known; however, three experiments were undertaken to 
determine the binding constants kon and koff, as well as the concentration of GGWSHW or KPLHALL 
binding peptide covalently attached to alginate. 
 
2.3.1 Imaging ellipsometry 
In order to determine binding constants using surface plasmon resonance (section 2.3.2), the optimal 
chemistry to fabricate an alginate monolayer on a gold surface was determined using imaging ellipsometry.  
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Gold sensor chips for imaging ellipsometry and surface plasmon resonance studies were prepared by 
electronbeam evaporation of 1 nm of chromium followed by application of 50 nm of high-purity gold onto 
BK7 optical glass microscope slides obtained from Fischer Scientific (Pittsburg, PA).  The glass slides 
were pre-cleaned with piranha solution for 30 min, rinsed, sonicated (5 min) in distilled H2O, and then 
transferred to an evaporation setup.  After metal evaporation, the substrates were sliced into 12.5 x 12.5 
mm pieces with a diamond-tipped stylus and stored in a desiccator at room temperature.  A second type of 
plain gold and carboxyl-terminated sensor chips, using SF10 glass, was purchased from Reichert Analytical 
Instruments (Reichert, Inc., Depew, NY).  Before chemically modifying these gold surfaces, the blank SPR 
chips were cleaned with acetone and ethanol and rinsed in distilled H2O. 
 
Amino undecanethiol (AUT) self-assembled monolayers (SAMs) were formed on the gold surfaces by 
incubating the substrates in 1 mM ethanolic solutions of the thiol compound between 18 and 22 h (room 
temperature, no agitation). Although 10-12 hours usually is sufficient for chemiabsorption of thiol 
compounds onto gold surfaces, the longer incubation time was used to allow the molecular films to self-
assemble into a crystalline-like solid phase.
37 Upon removal from the ethanol / thiol solution, the gold 
substrates were rinsed repeatedly in excess ethanol and blown dry using a stream of nitrogen gas. AUT 
SAM-modified substrates then were used immediately for fabrication of alginate sensor surfaces. 
 
Gold surfaces with an AUT SAM were activated by incubating a 1% (w/v) solution of UP LVG alginate in 
a 10 mM solution of EDC / NHS in PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4·7H2O, 1.4 mM 
KH2PO4, pH 7.2) for 5 minutes at room temperature.  The EDC-activated alginate was incubated overnight 
on the AUT-modified gold surface.  Subsequently, the substrates were washed with methanol to remove 
unbound alginate and blown dry with a stream of nitrogen gas. 
 
To determine the binding efficiency to gold sensor chips, various concentrations of modified and 
unmodified alginate were bound to the gold surface using this new binding protocol and imaged using 
imaging ellipsometry (IE).  The ellipsometric thickness of the AUT SAM and alginate layers assembled 
onto the gold substrates was estimated using a Nanofilm EP3 Imaging Ellipsometer.  The chemistry 
Owens  132 Materials & Methods     
previously described for attachment of alginate to gold has, to our knowledge, never been performed; 
imaging ellipsometry quantified the amount of polymer bound to the surface, and thus the effectiveness of 
this new coupling procedure.   
 
  
 
Figure 2.2. (Left) Imaging ellipsometry three-dimensional surface plot of alginate-modified surface;  
(Right) Variation in height of alginate across gold surface, in nm 
 
Measurements were performed using multiple angles of incidence (70°, 65°, 60°) from 400 to 600 nm using 
a xenon arc lamp.  Measurement at multiple angels generally improves confidence, as light travels different 
paths through the same film.  The ellipsometric parameters δ and ψ were determined, which correlate with 
the thickness of alginate on the sensor surface and the chemical composition of the surface layers, 
respectively.  The thickness of each layer immobilized on the SAM was estimated using theoretical 
modeling studies to fit the raw experimental data (δ and ψ), where δ shifts occur at approximately 1 degree 
per nanometer.  Data such as that shown in Figure 2.2 above were obtained for varying concentration of 
unmodified alginate in the EDC / NHS reaction from 0.125% to 1.25% in order to determine the optimal 
concentration of alginate to immobilize for surface plasmon resonance experiments. 
 
2.3.2 Surface plasmon resonance (SPR) 
To determine the biospecific interaction and affinity of the binding of each growth factor to its respective 
binding peptide (i.e. kon and koff), a surface plasmon resonance (SPR) biosensor was used.   
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2.3.2.1 SPR background 
As molecules are immobilized on the SPR sensor surface, the refractive index at the interface between the 
surface and a solution flowing over the surface changes, altering the angle at which reduced-intensity 
polarized light is reflected from the supporting glass plane.
38 The adsorption of biomolecules to the sensor 
surface results in a shift in the resonance angle, which is correlated with the refractive index of the solution 
flowing immediately adjacent to the gold-sensing surface; this change in angle is also proportional to the 
mass of bound material and is recorded in a sensorgram. 
 
When sample is passed over the sensor surface, the sensorgram shows an increasing response as molecules 
associate. The response remains constant when the interaction reaches equilibrium.  When sample is 
replaced by buffer, the response decreases as the interaction partners dissociate.
39 From these sensorgram 
profiles, kinetics (rates at which proteins interact) and affinity (how tightly binding peptides bind to the 
growth factor molecule) can be determined. 
 
2.3.1.2 KPLHALL-IGF-I interaction 
SPR measurements were performed on a model SR7000 Surface Plasmon Resonance Refractometer 
Instrument (Reichert, Inc., Depew, NY).  For this SPR instrument, a change in one pixel report unit 
corresponded to a change in refractive index (RI) of approximately 10
-6 RI.  The change in pixel units as a 
function of time was monitored in real time using a LabView-based software program.  Gold SPR sensor 
slides bound with modified and unmodified alginate were fabricated using chemistries that were 
characterized using imaging ellipsometry. 
 
Typically, the biomolecular interaction experiments for IGF-I and alginate modified with GGGKPLHALL 
(25° C) were carried out in buffer for 10 minutes per sample, using a constant flow rate of 25 μl / min over 
the surface of the SPR chip.  Concentrations of IGF-I ranged from 5 to 1000 nM.  PBST (PBS plus 0.05% 
v/v Tween 20) was used as both the sample and flow buffer.  After each binding experiment, the surface 
was regenerated with 40 mM HCl.  The sensorgram profiles were analyzed using Scrubber 2 software 
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(BioLogic Software, Campbell, Australia).  A representative sensorgram profile for this experiment is 
shown in Figure 2.3. 
 
 
 
Figure 2.3. Aligned SPR kinetic curves for multiple concentrations of IGF-I used to evaluate binding strength to the 
synthetic peptide GGGKPLHALL. 
 
2.3.2.3 GGWSHW-TGF-β1 interaction 
Due to difficulties with the Reichert instrument, SPR measurements on TGF- β1 were performed using a 
different SPR instrument, a BIA2000 Surface Plasmon Resonance Instrument (BIAcore AB, Uppsala, 
Sweden).  Due a difference in the sensor slides used for the SPR machines, CM5 carboxymethylated 
dextran chips and an ethylenediamine chemistry were used with the BIAcore system rather than AUT 
SAM-modified sensor slides.  The biomolecular interaction experiments (25° C) were carried out in HBS 
buffer for 7 minutes per sample using a constant flow rate of 10 μl / min.  Concentrations of TGF- β1 
ranged from 10 to 1000 nM.  After each binding experiment, the surface was regenerated with 40 mM HCl.  
Sensorgrams were generated and analyzed using BIAcore kinetic analysis software. 
 
2.3.3 Attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) 
To determine the density of binding peptides that were bound to the alginate (see Equation 1), and thus 
obtain more detailed information about the binding kinetics involved in this system, ATR-FTIR was 
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utilized.  By creating a standard curve using known concentrations of binding peptide, one can 
quantitatively determine the approximate concentration of binding peptide in a sample of modified alginate.  
ATR-FTIR measurements were performed on a Vertex 80v FTIR spectrometer (Bruker Optics Inc., 
Billerica, MA) equipped with a germanium crystal-based ATR accessory unit.  For each sample, a total of 
16 scans were taken.  Water was used to acquire the background spectrum.  All spectra were collected in 
absorbance mode. 
 
2.4 Controlled-release study 
2.4.1 Computer-aided modeling 
Using COMSOL Multiphysics Modeling Software version 1.1, Chemical Engineering Module (COMSOL 
Inc., Burlington, MA), a computational model for the diffusion of growth factor through alginate beads was 
created.  Using this computer-aided calculation of transient mass transfer, the rate at which growth factor 
was released from growth factor-binding alginate beads seeded with growth factor could be predicted using 
the non-covalent reaction between free growth factor (GFFree) and binding peptide (BP). 
 
2.4.1.1 Governing equations 
Three coupled reaction-diffusion equations were created to model diffusion kinetics of this system: 
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() () () ( Bound Free
Free
GF
Free GF koff GF BP kon
r
GF
r
r r
D
t
GF
× + × × − ⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
⎟
⎠
⎞
⎜
⎝
⎛
∂
∂
∂
∂
× × =
∂
∂ 2
2
1 )  (Equation  2) 
() () ( Bound Free
Bound GF koff GF BP kon )
t
GF
× − × × =
∂
∂      (Equation  3) 
() () ( Bound Free GF koff GF BP kon
t
BP
× + × × − =
∂
∂ )      (Equation  4) 
 
In media 
( ) ( )
⎟ ⎟
⎠
⎞
⎜ ⎜
⎝
⎛
⎟
⎠
⎞
⎜
⎝
⎛
∂
∂
∂
∂
× × =
∂
∂
r
GF
r
r r
D
t
GF Free
GF
Free 2
2
1        ( E q u a t i o n   5 )  
 
2.4.1.1 Schematic & initial conditions 
As diffusion is symmetric in all directions from the alginate bead, a one-dimensional model was created.  
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Alginate 
bead  Media 
0.00147 m                0.05 m 
Figure 2.4. Schematic (not drawn to scale) of one-dimensional model representing diffusion of growth factor from an 
alginate bead into a semi-infinite media bath. 
 
The radius of the media bath was progressively increased starting from 0.01 m until the free growth factor 
concentration in the alginate bead was found to be independent of the normal media surface radius.  This 
radius was determined to be 0.05 m.  A zero flux boundary condition could then be applied to the outer 
edge of the media: ()0 / = ∂ ∂ t GFFree .  Concentration of growth factor was assumed to be continuous at the 
alginate-media interface. 
 
Initially, the only species present are free growth factor, at , and free binding peptides, 
at , both in the alginate.  All other concentrations in all other regions are 
initially at zero.  Binding constants k
3 7 / 10 00 . 4 m mol
− ×
3 / 14 . 0 lg / 1 . 0 m mol a g mg =
on and koff were varied from 10 to 100 m
3 / (mol sec) and 10
-4 to 10
-1 
1/sec, respectively.  These binding constants are within the range obtained both through SPR and found in 
literature for other growth factor binding experiments.  To determine average concentration for all time 
points, the following integration was performed for each time point for 288 locations within the model: 
() volume bead Total
c dr r
c average inate a ∫ ×
=
2
, lg
4π
,   (Equation  6) 
where r is the linear coordinate along the horizontal axis of the model.  Thus, controlled-release of growth 
factor from alginate beads was modeled.  Using results from the computer model, an experimental 
controlled diffusion study was designed using alginate beads and ELISA. 
 
2.4.2 Enzyme-linked ImmunoSorbent assay (ELISA) 
In order to determine the functionality of this binding peptide-modified alginate in macro-scale situations, a 
controlled diffusion study was performed.  To determine the kinetics of growth factor release from peptide-
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modified alginate, growth factors were suspended in 2% peptide-modified alginate and analyzed for 
diffusion into the surrounding media.  Unmodified LVG alginate beads acted as a control.  Kinetic studies 
were performed using both human recombinant TGF-β1 and IGF-I.  Peptide-modified alginate was diluted 
with Ultra Pure LVG alginate at 0.1 g TGF- β1 alginate: 1 g LVG alginate and 0.5 g IGF-I alginate: 1 g 
LVG alginate.  Each growth factor was reconstituted in phosphate buffered saline with 0.1% BSA to a 
concentration of 10 ng TGF- β1 / ml PBS and 100 ng IGF-1 / ml PBS. The alginate was mixed with the 
reconstituted growth factor to create a 2% w/v (20 mg / ml) alginate solution.  The alginate solution was 
sterile filtered using a 0.22 µm syringe filter. 
 
Alginate beads were formed by dropping the prepared modified or unmodified alginate from a syringe 
(Becton-Dickson, Franklin Lakes, NJ) using a 22 gauge needle into a 102 mmol / L CaCl2 solution (102 
mM d-hydrous CaCl2, 15 mM HEPES) for 10 minutes.
40  The beads were washed 3 times in 1 ml of sterile 
PBS to remove any growth factor that had not been incorporated into the bead.  The beads were placed into 
24-well culture dishes, each well containing 1 bead.  The beads then were suspended in 1 ml of standard 
culture medium consisting of Dulbecco’s Modified Eagle Medium (DMEM, high glucose) (Gibco, 
Invitrogen, Carlsbad, CA), 1% Insulin Transferrin Selenium (ITS), 0.1% Bovine Serum Albumin (BSA), 
100 U / ml penicillin, and 100 µg / ml streptomycin. 
 
The plates were maintained at 37° C in the tissue culture incubator.  The medium was completely removed 
from the wells at five time points (2, 4, 8, 16, and 25 days), and replaced by fresh medium.  An ELISA was 
used to measure the amount of growth factor that was released into the medium at various time points.  
 
2.5 Cellular Study 
To determine if covalent modification of alginate with binding peptides improves cell viability and ECM 
production, chondrocytes and mesenchymal stem cells (MSCs) were seeded in unmodified LVG alginate 
and binding peptide-modified alginate.  Biochemical assays were utilized to determine the cellular effect of 
the modified-alginate scaffold. 
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2.5.1 Chondrocyte and MSC isolation and seeding 
Bovine cartilage was harvested from the femoropatellar groove of 1-3-day-old calves.  The harvested tissue 
was digested for 18 hours in Dulbecco’s Modified Eagle Medium (DMEM) containing 3 mg /ml 
collagenase at 37°C and 5% CO2.  The digest was filtered with a 100 µm cell strainer (BD Bioscience, 
Bedford, MA) and then centrifuged at 412g for 7 minutes.  The resulting cell pellet was washed twice with 
Dulbecco’s phosphate-buffered saline (PBS) (Mediatech, Herndan, VA).   
 
Bone marrow was aspirated from the iliac crest and sternum of euthanized horses from the Cornell 
University School of Veterinary Medicine.  Red blood cells were lysed and the remaining nucleated cells 
were plated in tissue culture flasks to allow for adhesion of cell populations.
41 After 3 days, non-adherent 
cells were removed and the remaining cells were expanded for either 2 or 3 passages for seeding into 
alginate scaffolds. 
 
Cell number for both cell types was determined using a hemocytometer (Hausser Scientific, Horsham, PA), 
and cell viability was determined using trypan blue dye.  Chondrocytes and MSCs were then suspended 
into 10 mg / ml of LVG alginate or binding peptide modified-alginate at a seeding density of 6 x 10
7 cells / 
ml 
42.  This cell-seeded alginate solution was cross-linked using the same alginate bead procedure as 
outlined in the ELISA section outlined in this thesis, with or without growth factor addition.  Alginate 
beads were removed from culture at 0, 1, and 2 weeks and frozen at -80°C for biochemical analysis.  
 
2.5.2 Biochemical analysis 
Frozen samples were weighed on a microbalance and digested in 1 ml of 0.1 M sodium phosphate, 10 mM 
cysteine hydrochloride, and 3.8 U / ml papain at 60°C for 18 hours.  Resulting biochemical contents were 
normalized to the wet weight of the sample. 
 
2.5.2.1 Glycosaminoglycan (GAG) Assay 
The glycosaminoglycan (GAG) content of the digests were measured as a marker for proteoglycans (key 
components of cartilage as discussed in the introduction of this thesis) using well-established methods.
43  
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The assay was carried out in 96-well plates.  In each well, 50 µl of digest was mixed with 250 µl of dye 
containing 16 mg / L 1,9-dimethylmethylene blue (DMMB) and 3.04 g / L glycine (pH 1.5).  The 
absorbance was read at 595 nm using a microplate reader.  Chondroitin-6-sulfate from shark cartilage was 
used to construct the standard curve. 
 
2.5.2.2 DNA Assay 
DNA content was measured as a marker of cell quantity (i.e. general cell proliferation and viability) using a 
Hoechst dye.
44 In each well, 190 µg / ml Hoechst 33258 dye in tris(hydroxymethyl)aminomethane EDTA 
saline (TES) buffer was added to 10 µl of the digested samples.  Calf thymus DNA was used as a standard 
and DNA contents were determined by reaction with the Hoechst dye.  Fluorescence was measured with an 
excitation wavelength at 348 nm and emission wavelength at 456 nm. 
 
2.5.2.3 Hydroxyproline Assay 
Hydroxyproline is a major ECM component that is specific to collagen.  Therefore, hydroxyproline content 
was measured as a marker of collagen and ECM production.  The hydroxyproline content of digests was 
measured using previously described methods.
45 100 µl of each sample’s digest was hydrolyzed in 100 µl 
of 2 N NaOH at 110°C for 18 hours.  Afterwards, 20 µl 5N HCl, 100 µl 0.01 M CuSO4, 100 µl 2.5 N 
NaOH, and 100 µl 6% H2O2 were added to the digested hydrolyzed sample in microfuge tubes.  The tubes 
were allowed to sit at room temperature for 5 minutes, vortexed, and placed in a heat block at 80°C for 5 
minutes.  The tubes were then placed in an ice bath to cool to room temperature and 400 µl of 3N H2SO4 
and 200 µl of 5 mg / ml p-dimethylaminobenzaldehyde in n-propanol (DMAB) were added to each tube.  
All assays were carried out in 96-well plates (Nalge Nunc, Rochester, NY).  Each well of a 96-well plate 
was filled with 200 µl of a treated sample and absorbance was measured at 540 nm. 
 
2.6 Statistics 
Statistical analysis of biochemical data was completed using a two-way analysis of variance for 
chondrocytes data, and a t-test for MSC data (p < 0.05 for significance), using SAS Statistical Analysis 
System (SAS Institute, Cary, NC). 
Owens  213 Results     
3.1 Binding kinetics study 
3.1.1 Imaging Ellipsometry 
The optical thickness of the AUT SAM was found to be 11.0 ± 2.0 Å for both the self-made and Reichert 
SPR chips; this falls within the range of ellipsometric thickness values that Mark et al. had observed 
previously.
37 The thickness measurement values suggest that a single monolayer of alginate was assembled 
on the gold substrates, confirming that successful derivatization of the gold sensor surface had occurred.  
The thickness of the layer of alginate, as measured by δ shifts, increased as the concentration of alginate 
used in the initial chemical procedure increased.  The increase in Ψ with alginate concentration was not 
significant.  The delta plot begins to plateau as the alginate concentration increases, demonstrating that the 
surface of the gold chip was approaching saturation with bound alginate, and steric hindrances due to 
repulsion of charged alginate monomers made a larger impact at these higher concentrations. 
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Figure 3.1.  Measured shifts of the ellipsometric parameters delta and psi, which represent changes in thickness of 
surface layer and changes in chemical composition, respectively. 
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3.1.2 Surface Plasmon Resonance 
3.1.2.1 KPLHALL-IGF-I interaction 
Results were obtained using the Reichert SPR system to determine kinetic binding parameters between 
IGF-I and its respective binding peptide, GGGKPLHALL.  The initial results suggest that the binding of 
this new IGF-I binding peptide was quite strong, with a range in overall dissociation constant typically 
between 50 nM and 2 µM. 
 
 
kon 
1 / Ms 
 
koff 
1 / s  KD Res SD 
2.09E+05 1.98E-04  947.4  pM 1.216 
52786.8 1.30E-03  24.55  nM  1.224 
31179.5 1.52E-03  48.73  nM  1.458 
12291.7 7.06E-04  57.44  nM  1.507 
7941.7 1.00E-03  125.9  nM  3.425 
5.4E+03 1.85E-3  340.0  nM  0.003 
1181.1 1.53E-03  1.295  µM  0.811 
912.8 1.62E-03  1.777  µM  1.477 
33.78 4.79E-03  141.1  µM  2.244 
3.926 1.00E-03  254.7  µM  2.308 
 
Table 3.1. Compilation of representative SPR kinetics values for KPLHALL-modified alginate interaction with IGF-1. 
 
However, in late fall 2006, it was determined that these SPR curves may have depicted considerably more 
binding than was actually present, due to non-specific binding within the Reichert SPR instrument.  
Qualitatively, however, a strong enhancement of signal intensity was obtained using the peptide-modified 
alginate surface, and the presence of the binding peptides on the alginate layer increased the amount of 
growth factor that was captured and retained on the sensor surface. 
 
3.1.2.2 GGWSHW-TGF-β1 interaction 
Results obtained from the BIAcore system on the GGWSHW-modified alginate (to bind TGF-β1) also 
show greater binding of growth factor to modified alginate than to unmodified alginate; however, 
quantitative determination of binding constants for this GGWSHW-TGF-β1 system was not accomplished. 
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3.1.3 ATR-FTIR 
In the low-frequency regions of the IR spectra, the most informative features relevant for this study were 
the stretching and bending signals from amine and amide functional groups.  The spectrum for the 
unmodified alginate shows only a weak relative absorption band centered at 1650 cm
-1, which is assigned 
to amide bending.  The observation of stronger amide absorption bands in the modified alginate is 
consistent with the presence of surface-immobilized proteins.  In the fingerprint region of the peptide 
sequence, there are two main features occurring at 1650 and 1540 cm
-1 that are attributable to the amide I 
and II stretchings, respectively.  Determination of density of binding peptides bound in modified alginate 
using this technique will be continued summer 2007 by other members of the laboratory.  UV-VIS 
spectroscopy analysis showed an approximate concentration of 0.1 mg / g alginate for GGWSHW. 
 
 
 
Figure 3.2. ATR-FTIR scan of GGGK(Dde)PLHALL peptide.  Absorption bands occurring in the amide 
band regions of the IR spectra are shown in blue. 
 
3.2 Controlled-release study 
3.2.1 Computer-aided modeling 
The following plots were generated using the COMSOL model: 
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Figure 3.3, 3.4. Concentrations in media for various values of kon  and koff for concentration of TGF-β1 in media. 
For different kon values, the diffusion profiles differed only slightly. 
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3.2.2 ELISA 
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Figure 3.6. Release of IGF-I into media over time as determined by ELISA.  Bath was collected at 2, 4, 8, 16, and 25 
days (n = 3).  Error bars are standard error of the mean for all graphs. 
 
Because growth factors are non-covalently bound to their respective synthetic peptide on modified alginate 
beads, these beads show a markedly different concentration profile than beads composed of unmodified 
alginate.
46  Beads were 0.02 ml in volume with 2 ng total IGF-I per bead.   
 
The ELISA for TGF-￿1 was not able to detect growth factor release from either GGWSHW-modified or 
unmodified alginate beads.  Lower growth factor seeding density (10 nM versus 100 nM for IGF-I-seeded 
beads) may have played a role.  Additionally, transformation of TGF-￿1 from latent to active form may 
have created experimental error leading to lack of signal. 
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3.3 Cellular study 
3.3.1 GAG   
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Figure 3.7. Total GAG content for chondrocytes, normalized by wet weight. 
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Figure 3.8 Total GAG content for MSCs, normalized by wet weight. 
 
For chondrocytes, GAG content was found to be higher in week 1 (p = 0.04) and week 2 (p = 0.01) with 
KPLHALL than for LVG.  Additionally, increase in GAG content from week 0 to week 2 was greater for 
KPLHALL than LVG (p = 0.01).  A potentially confounding factor was that GAG content was lower in 
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week 2 with IGF-1 than for no growth factor addition (p = 0.03).  Typically, one would expect IGF-I to 
increase cellular proliferation for both week 1 and week 2.  The drop in week 2 may be due to an 
interaction between the alginate type and the growth factor treatment.  Addition of IGF-1 reduced GAG 
with KPLHALL but had little effect on GAG with LVG (Interaction p = 0.03).  
 
For MSCs, GAG content was higher in week 2 for GGWSHW than for LVG (p = 0.01), and the decrease in 
GAG content from week 1 to week 2 was greater for LVG than for GGWSHW (p = 0.01).  
 
When one has an interaction, responses to main effects (either to IGF-1 addition or differences between 
KPLHALL alginate and LVG alginate) may be biased; in the presence of an interaction, one should 
exercise caution when interpreting main effects.  Although there is an evident treatment interaction over 
time, changes in values over time are difficult to interpret, and changes later in time can be biased by 
changes earlier in time.  
 
3.3.2 DNA 
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Figure 3.9. Total DNA content for chondrocytes, normalized by wet weight. 
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Figure 3.10. Total DNA content for MSCs, normalized by wet weight. 
 
For chondrocytes, DNA content was higher in week 1 for KPLHALL than for LVG (p = 0.01).  Adding 
IGF-1 to KPLHALL increased the degree of change in DNA from week 0 to week 1, but the addition of 
IGF-1 to LVG decreased this change over time (Interaction p = 0.01).  Neither alginate type nor growth 
factor treatment made a significant difference in total DNA content for MSCs. 
 
3.3.3 Hydroxyproline 
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Figure 3.11. Total hydroxyproline content for chondrocytes, normalized by wet weight. 
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Figure 3.12. Total hydroxyproline content for MSCs, normalized by wet weight. 
 
Hydroxyproline content increased significantly in modified alginate with growth factors (p = 0.02).  
Neither alginate type nor growth factor treatment made a significant difference in total DNA content for 
MSCs. 
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Using imaging ellipsometry and SPR, the binding constants between peptide-modified alginate and their 
respective growth factors was determined to be on the order of 100 nM to 1 µM.  Comparing ELISA results 
to the modeling study, it appears that this level of binding is also present in IGF-1-modified alginate beads.  
The biochemical data demonstrates that binding peptide-modified alginate increases cell production of 
GAG, DNA, and hydroxyproline for certain time points.  
 
The interaction between IGF-1 and the KPLHALL alginate response implies that response to IGF-1 
addition differed depending on whether the cells received the KPL or the LVG treatment.  Cells that were 
grown in KPLHALL-modified alginate without IGF-1 produced much more GAG than any other treatment 
class, suggesting that the IGF-1 produced by the chondrocytes is being bound by the modified-alginate and 
facilitating its growth. 
 
As cells were only grown for a period of two weeks, long-term functional outcome is still a significant 
question. Future directions for research on this peptide-modified alginate system include continuation of 
ATR FT-IR studies, as well as repeating cell culture experiments with chondrocytes.   
 
This work is the first step in creating and characterizing a synthetic ECM, using alginate as the base 
material, in which ligand type and density may be varied readily, and the cellular response specifically 
modified.  In contrast to many previous systems, these alginate hydrogels may provide a practical system to 
transfer cell-material interaction studies into clinically relevant biomaterials.  Alginate currently is being 
utilized in a number of trials to transplant multiple cell types and to treat biochemical or structural 
deficiencies; alginate matrices optimized for particular growth factor interactions may be readily used in 
these kinds of applications.   
 
By incorporating specific growth factors within the alginate scaffold, without the adsorption of additional 
proteins that possibly could interfere with cellular behavior, cellular interactions can be characterized more 
thoroughly.  For example, the IGF system plays a central role in many aspects of tumorigenesis.  A better 
understanding of this complex system, which could be aided by alginate scaffolds that bind IGF-I, could 
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facilitate the development of novel approaches to diagnose and treat various human cancers and other 
diseases.  Ultimately, the goal will be to produce a delivery system using growth factors, chondrocytes or 
mesenchymal stem cells, and a synthetic matrix of peptide-bound alginate to create a scaffold that can also 
be used to restore articular cartilage at minimal cost and patient morbidity.  When placed in the correct 
combination and with the right mechanical stimuli, true restoration of articular cartilage may be ultimately 
achieved. 
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